Skip to content
Altius – Lifestyle
Author:
Whitehawk Therapeutics
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
May 30, 2026
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
May 28, 2026
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
May 21, 2026
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
May 20, 2026
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
May 15, 2026
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
May 13, 2026
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
May 7, 2026
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
April 19, 2026
Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
April 16, 2026
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
April 10, 2026
1
2
Next Page
→